CD74 promotes the formation of an immunosuppressive tumor microenvironment in triple-negative breast cancer in mice by inducing the expansion of tolerogenic dendritic cells and regulatory B cells
PLOS Biology · 22.11.2024 · 22 (11) · e3002905
DOI: 10.1371/journal.pbio.3002905 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Biology, online erschienen am 22.11.2024. Verfasst von Bianca Pellegrino und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Dendritic Cells, Tumor Microenvironment, Antigens, Differentiation, B-Lymphocyte. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NCATS NIH HHS, BLRD VA.
Abstract (Originalsprache)
CD74 is a cell-surface receptor for the cytokine macrophage migration inhibitory factor (MIF). MIF binding to CD74 induces a signaling cascade resulting in the release of its cytosolic intracellular domain (CD74-ICD), which regulates transcription in naïve B and chronic lymphocytic leukemia (CLL) cells. In the current study, we investigated the role of CD74 in the regulation of the immunosuppressive tumor microenvironment (TME) in triple-negative breast cancer (TNBC). TNBC is the most aggressive breast cancer subtype and is characterized by massive infiltration of immune cells to the tumor microenvironment, making this tumor a good candidate for immunotherapy. The tumor and immune cells in TNBC express high levels of CD74; however, the function of this receptor in the tumor environment has not been extensively characterized. Regulatory B cells (Bregs) and tolerogenic dendritic cells (tol-DCs) were previously shown to attenuate the antitumor immune response in TNBC. Here, we demonstrate that CD74 enhances tumor growth by inducing the expansion of tumor-infiltrating tol-DCs and Bregs. Utilizing CD74-KO mice, Cre-flox mice lacking CD74 in CD23 + mature B cells, mice lacking CD74 in the CD11c + population, and a CD74 inhibitor (DRQ), we elucidate the mechanism by which CD74 inhibits antitumor immunity. MIF secreted from the tumor cells activates CD74 expressed on DCs. This activation induces the binding of CD74-ICD to the SP1 promotor, resulting in the up-regulation of SP1 expression. SP1 binds the IL-1β promotor, leading to the down-regulation of its transcription. The reduced levels of IL-1β lead to decreased antitumor activity by allowing expansion of the tol-DC, which induces the expansion of the Breg population, supporting the cross-talk between these 2 populations. Taken together, these results suggest that CD74 + CD11c + DCs are the dominant cell type involved in the regulation of TNBC progression. These findings indicate that CD74 might serve as a novel therapeutic target in TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
- Yale Cancer Center and School of Medicine, New Haven, Connecticut, United States of America.
- Neuroimmunology Research, VA Portland Health Care System, Portland, Oregon, United States of America.
- Department of Neurology, Oregon Health & Science University, Portland, Oregon, United States of America.
- Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, United States of America.
- Insitute of Pathology, Sourasky Medical Center, Tel Aviv, Israel.
ORCID-Profile: Idit Shachar
Förderung
- NIAMS NIH HHS
- NCATS NIH HHS
- BLRD VA
- NIAID NIH HHS
- Israel Science Foundation
- U.S. Department of Veterans Affairs
- BLR&D Merit Review for Pre-IND studies of Drugs and Biologics Award
- Senior Research Career Scientist Award
Zitieren
APA
Pellegrino, B., David, K., Rabani, S., Lampert, B., Tran, T., Doherty, E., Piecychna, M., Meza-Romero, R., Leng, L., Hershkovitz, D., Vandenbark, A. A., Bucala, R., Becker-Herman, S., & Shachar, I. (2024). CD74 promotes the formation of an immunosuppressive tumor microenvironment in triple-negative breast cancer in mice by inducing the expansion of tolerogenic dendritic cells and regulatory B cells. PLOS Biology, 22(11), e3002905. https://doi.org/10.1371/journal.pbio.3002905
Vancouver
Pellegrino B, David K, Rabani S, Lampert B, Tran T, Doherty E, et al. CD74 promotes the formation of an immunosuppressive tumor microenvironment in triple-negative breast cancer in mice by inducing the expansion of tolerogenic dendritic cells and regulatory B cells. PLOS Biology. 2024;22(11):e3002905. doi:10.1371/journal.pbio.3002905
BibTeX
@article{Pellegrino2024,
author = {Pellegrino, Bianca and David, Keren and Rabani, Stav and Lampert, Bar and Tran, Thuy and Doherty, Edward and Piecychna, Marta and Meza-Romero, Roberto and Leng, Lin and Hershkovitz, Dov and Vandenbark, Arthur A and Bucala, Richard and Becker-Herman, Shirly and Shachar, Idit},
title = {CD74 promotes the formation of an immunosuppressive tumor microenvironment in triple-negative breast cancer in mice by inducing the expansion of tolerogenic dendritic cells and regulatory B cells},
journal = {PLOS Biology},
year = {2024},
volume = {22},
number = {11},
pages = {e3002905},
doi = {10.1371/journal.pbio.3002905}
}
EUVIMED